Incyte Announces Positive 52-Week Data from Phase 2b Study E

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Delaware , Berlin , Germany , Paris , France General , France , Khaled Ezzedine , Kurt Brown , Department Of Dermatology , Exchange Commission , European Academy Of Dermatology , Povorcitinib Global Program Head Incyte , European Academy , Late Breaking News , Total Vitiligo Area Scoring Index , Vitiligo Area Scoring Index , Vice President , Povorcitinib Global Program Head , Henri Mondor Hospital ,